<DOC>
	<DOCNO>NCT01730222</DOCNO>
	<brief_summary>Four-drug combo yield statistically significant improvement progression-free survival overall survival compare gemcitabine patient advance pancreatic adenocarcinoma . Nab-Paclitaxel show promising antitumor activity patient pancreatic cancer . Given synergism taxanes gemcitabine , fluoropyrimidines platinating agent role nab-Paclitaxel 4-drug regimen explore . The aim trial determine recommend dose nab-paclitaxel combination cisplatin , capecitabine , gemcitabine , PAXG regimen ( Phase I ) , evaluate feasibility activity PAXG regimen patient stage III IV pancreatic cancer .</brief_summary>
	<brief_title>A Phase I-II Study PAXG Stage III-IV Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>OBJECTIVES : PHASE I : determine recommend phase 2 dose nab-paclitaxel combination cisplatin , capecitabine , gemcitabine . PHASE II : evaluate feasibility activity PAXG regimen term 6-months progression-free survival patient stage III IV pancreatic cancer . OUTLINE Phase I - dose find single institution trial , follow randomize open label multicenter phase II trial . Phase II : Patients stratify stage ( III v IV ) CA19.9 level ( &lt; 10 x ULN versus &gt; 10 x ULN ) ; Patients randomly assign receive PAXG ( arm A ) gemcitabine-nab-paclitaxel regimen ( arm B ) . Treatment plan ( phase II ) : Arm A : PAXG every 4 week ( 1 cycle ) : cisplatin 30 mg/m2 day 1 15 , nab-paclitaxel RP2D day 1 15 , capecitabine 1250 mg/ m2 day 1-28 , gemcitabine 800 mg/ m2 day 1 15 . Arm B : Gemcitabine + nab-paclitaxel every 4 week ( 1 cycle ) : gemcitabine 1000 mg/m2 day 1 , 8 15 ; nab-paclitaxel 125 mg/mq day 1 , 8 15 . Treatment administer maximum 6 cycle clinical benefit .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Pathologic diagnosis pancreatic adenocarcinoma Stage III IV disease Age &gt; 17 &lt; 76 year Karnofsky Performance Status &gt; 50 Measurable disease ( phase II part ) Adequate bone marrow ( GB &gt; 3500/mm3 , neutrophil &gt; 1500/mm3 ; platelet &gt; 100000/mm3 ; hemoglobin &gt; 10 g/dl ) , liver ( total bilirubin &lt; 2 mg/dL ; SGOT e SGPT &lt; 3 UNL ) kidney function ( serum creatinin &lt; 1.5 mg/dL ; ) Written inform consent previous chemotherapy concurrent treatment experimental drug previous concurrent malignancy sit exception surgically cure carcinoma insite cervix basal squamous cell carcinoma skin neoplasm without evidence disease least 5 year symptomatic brain metastasis history interstitial lung disease presence serious disease compromise safety ( cardiac failure , previous myocardial infarction within prior 6 month , cardiac arrhythmia , history psychiatric disability ) pregnancy lactate History connective tissue disorder ( eg , lupus , scleroderma , arteritis nodosa ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>pancreatic adenocarcinoma</keyword>
	<keyword>stage III disease</keyword>
	<keyword>stage IV disease</keyword>
	<keyword>chemotherapy</keyword>
</DOC>